Alkermes
ALKSAlkermes is a global biopharmaceutical company focused on developing and commercializing innovative medicines for neurological disorders and neuroscience.
Earnings
Next report
Oct 27, 2026 (in 3 months)Financials
Q2 2026Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
Alkermes is a global biopharmaceutical company focused on developing and commercializing innovative medicines for neurological disorders and neuroscience. The company maintains a portfolio of proprietary products for schizophrenia, bipolar I disorder, alcohol and opioid dependence, and narcolepsy, while leveraging its proprietary drug delivery technologies through strategic licensing and manufacturing partnerships.
A leading neuroscience-focused biopharmaceutical firm with a strong portfolio of long-acting injectable treatments and proprietary drug delivery platforms like NANOCRYSTAL and LINKERX.
Questions, answered.
- What is Alkermes's market cap?
- Alkermes (ALKS) has a market capitalization of $8.8B and trades on NASDAQ.
- What is Alkermes's revenue and profitability?
- Alkermes generated $1.7B in trailing twelve-month revenue with net income of $66.1M, representing a net margin of 4.0%. Gross margin stands at 84.6%. These figures are based on the Q2 2026 filing.
- Who are Alkermes's competitors?
- Alkermes's key competitors include Axsome Therapeutics, Indivior plc, AbbVie, and others. These companies compete in similar markets and product categories.
- Who does Alkermes partner with?
- Alkermes's notable partners include Janssen Pharmaceuticals, Inc., Biogen, Jazz Pharmaceuticals, and others.
- What subsidiaries does Alkermes have?
- Alkermes's subsidiaries include Avadel Pharmaceuticals plc.
- Where is Alkermes headquartered?
- Alkermes is headquartered in Ireland and employs approximately 2,100 people. It has been publicly traded since 1991.
